AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating restated by stock analysts at Deutsche Bank AG in a report issued on Tuesday. They currently have a GBX 5,300 ($68.45) price objective on the biopharmaceutical company’s stock. Deutsche Bank AG’s price target would suggest a potential upside of 15.68% from the company’s current price.

A number of other brokerages have also weighed in on AZN. Morgan Stanley reiterated an “overweight” rating and set a GBX 5,600 ($72.32) target price on shares of AstraZeneca plc in a research note on Friday, June 23rd. UBS Group AG set a GBX 5,150 ($66.51) target price on shares of AstraZeneca plc and gave the company a “neutral” rating in a research note on Tuesday, June 27th. Shore Capital reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday, June 21st. Barclays PLC reiterated an “overweight” rating and set a GBX 6,000 ($77.49) target price on shares of AstraZeneca plc in a research note on Monday, June 5th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of AstraZeneca plc in a research note on Monday, June 5th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of GBX 4,892.19 ($63.18).

Shares of AstraZeneca plc (LON:AZN) opened at 4581.50 on Tuesday. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00. The stock’s market capitalization is GBX 58.00 billion. The company’s 50 day moving average price is GBX 4,622.79 and its 200-day moving average price is GBX 4,873.63.

ILLEGAL ACTIVITY WARNING: This report was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/09/05/astrazeneca-plc-azn-rating-reiterated-by-deutsche-bank-ag.html.

In related news, insider Nazneen Rahman acquired 39 shares of the company’s stock in a transaction on Thursday, July 27th. The stock was acquired at an average price of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.